Efficacy, safety, and tolerability of amodiaquine plus sulphadoxine-pyrimethamine used alone or in combination for malaria treatment in pregnancy: a randomised trial

Lancet

Volumn 368, Issue 9544, 2006, Pages 1349-1356

  Tagbor, Harry ^a   Bruce, Jane ^c   Browne, Edmund ^b   Randal, Anna ^c   Greenwood, Brian ^c   Chandramohan, Daniel ^c  

^a St Theresa's Hospital   (Ghana)

^b KWAME NKRUMAH UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Ghana)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMODIAQUINE; CHLOROQUINE; FANSIDAR;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ABNORMALLY LOW SUBSTRATE CONCENTRATION IN BLOOD; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BLOOD DYSCRASIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EAR MALFORMATION; FEMALE; FOLLOW UP; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GESTATIONAL AGE; GHANA; HEMOGLOBIN BLOOD LEVEL; HUMAN; LEUKOCYTE COUNT; LIVER FUNCTION; LIVER TOXICITY; LYMPHOCYTE; MAJOR CLINICAL STUDY; MALARIA; MUSCLE WEAKNESS; NAUSEA; NEUTROPHIL; PARASITEMIA; PLASMODIUM FALCIPARUM; POLYDACTYLY; POLYMERASE CHAIN REACTION; PREGNANCY; PRENATAL CARE; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT FAILURE; VOMITING;

EID: 33749518243     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(06)69559-7     Document Type: Article

References (24)

1. World Health Organization. A strategic framework for malaria prevention and control during pregnancy in the African region (2004), WHO Regional Office for Africa, Brazzaville, Democratic Republic of the Congo AFR/MAL/04/01
2. Shulman C., T Marshall E., Dorman J., et al. Malaria in pregnancy: adverse effects on haemoglobin levels and birthweight in primigravidae and multigravidae. Trop Med Int Health 6 (2001) 770-778
3. Steketee R., Nahlen B., Parise M., and Menendez C. The burden of malaria in pregnancy in malaria-endemic areas. Am J Trop Med Hyg 64 (2001) 28-35
4. Garner P., and Gulmezoglu A. Prevention versus treatment for malaria in pregnant women. Cochrane Database Syst Rev 2 (2000) CD000169
5. World Health Organization. Assessment of the safety of artemisinin compounds in pregnancy (2003), WHO, Geneva WHO/CDS/MAL 2003.1094, WHO/RBM/TDR/Artemisinin/03.1
6. Mengesha T., and Makonnen E. Comparative efficacy and safety of chloroquine and alternative antimalarial drugs: a meta-analysis from six African countries. East Afr Med J 76 (1999) 314-319
7. Muller O., van Hensbroek M., Jaffar S., et al. A randomized trial of chloroquine, amodiaquine and pyrimethamine-sulphadoxine in Gambian children with uncomplicated malaria. Trop Med Int Health 1 (1996) 124-132
8. EANMAT. The efficacy of antimalarial monotherapies, sulphadoxine-pyrimethamine and amodiaquine in east Africa: implications for sub-regional policy. Trop Med Int Health 8 (2003) 860-867
9. Baird J. Effectiveness of antimalarial drugs. N Engl J Med 352 (2005) 1565-1577
10. Thomas F., Erhart A., and D'Alessandro U. Can amodiaquine be used safely during pregnancy?. Lancet Infect Dis 4 (2004) 235-239
11. Thet N., Hla W., and Yin Yin N. Falciparum malaria and pregnancy: relationship and treatment response. S Asian J Trop Med Public Health 19 (1988) 253-258
12. Steketee R., Brandling-Bennett A., Kaseje D., Schwartz I., and Churchill F. In vivo response of Plasmodium falciparum to chloroquine in pregnant and non-pregnant women in Siaya District, Kenya. Bull World Health Organ 65 (1987) 885-890
13. Snounou G., Zhu N., Siripoon W., et al. Biased distribution of msp1 and msp2 allelic variants in Plasmodium falciparum populations in Thailand. Trans R Soc Trop Med Hyg 93 (1999) 369-374
14. Marfo C. Ghana malaria baseline situational analysis survey report (2001), MOH/GHANA, WHO-RBM/AFRO, Accra, Ghana
15. Mockenhaupt F., Ehrhardt S., Dzisi S., et al. A randomized, placebo-controlled, double-blind trial on sulfadoxine-pyrimethamine alone or combined with artesunate or amodiaquine in uncomplicated malaria. Trop Med Int Health 10 (2005) 512-520
16. Oduro A., Anyorigiya T., Hodgson A., et al. A randomized comparative study of chloroquine, amodiaquine and sulphadoxine-pyrimethamine for the treatment of uncomplicated malaria in Ghana. Trop Med Int Health 10 (2005) 279-284
17. Olliaro P., Nevill C., LeBras J., et al. Systematic review of amodiaquine treatment in uncomplicated malaria. Lancet 348 (1996) 1196-1201
18. Meerman L., Ord R., Bousema J., et al. Carriage of chloroquine-resistant parasites and delay of effective treatment increase the risk of severe malaria in Gambian children. J Infect Dis 192 (2005) 1651-1657
19. Kollaritsch H., Stemberger H., Mailer H., et al. Tolerability of long-term malaria prophylaxis with the combination mefloquine+sulfadoxine+pyrimethamine (Fansimef): results of a double blind field trial versus chloroquine in Nigeria. Trans R Soc Trop Med Hyg 82 (1988) 524-529
20. Phillips-Howard P., and West L. Serious adverse drug reactions to pyrimethamine-sulphadoxine, pyrimethamine-dapsone and to amodiaquine in Britain. J R Soc Med 83 (1990) 82-85
21. Hatton C., Peto T., Bunch C., et al. Frequency of severe neutropenia associated with amodiaquine prophylaxis against malaria. Lancet 327 (1986) 411-414
22. Neftel K., Woodtly W., Schmid M., Frick P., and Fehr J. Amodiaquine induced agranulocytosis and liver damage. BMJ 292 (1986) 721-723
23. Rhodes E., Ball J., and Franklin M. Amodiaquine induced agranulocytosis: inhibition of colony growth in bone marrow by antimalarial agents. BMJ 292 (1986) 717-718
24. Sturchler D., Schar M., and Gyr N. Leucopenia and abnormal liver function in travellers on malaria chemoprophylaxis. J Trop Med Hyg 90 (1987) 239-243